TrialInvestigational new drugs2017

Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.

Kosei Hasegawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.